

DAFTAR PUSTAKA

- Abbas, A.K., Lichtman, A.H. and Pillai, S. (2024) *Basic Immunology: Functions and Disorders of The Immune System*. 7th Editio. Canada: Elsevier Inc.
- Adane, T. and Enawgaw, B. (2023) "Human leukocyte antigen alloimmunization prevention mechanisms in blood transfusion," *Asian Journal of Transfusion Science*, 17:264-72. Available at: https://doi.org/10.4103/ajts.ajts_144_21.
- Agarwal, N. *et al.* (2014) "Prevalence of platelet reactive antibodies in patient ' s refractory to platelet transfusions," *Asian Journal of Transfusion Science*, 8(2), pp. 126–127. Available at: <https://doi.org/10.4103/0973-6247.137453>.
- Alcaina, P.S. (2020) "Platelet transfusion: And update on challenges and outcomes," *Journal of Blood Medicine*, 11, pp. 19–26. Available at: <https://doi.org/10.2147/JBM.S234374>.
- Amalia, A., Hafy, Z. and Liana, P. (2021) "Perbandingan Proporsi Antibodi Ireguler pada Pasien Multitransfusi dan Pasien Non Multitransfusi di UTD RSUP Dr. Mohammad Hoesin Palembang," *Jurnal Surya Medika*, 7(1), pp. 9–14. Available at: <https://doi.org/10.33084/jsm.v7i1.2630>.
- Andriastuti, M., Chozie, N.A. and Rahmani, S. (2018) "Laporan kasus berbasis bukti Efektivitas Transfusi Trombosit Hasil Uji Silang Serasi," *Sari Pediatri*, 20(1). Available at: <https://doi.org/10.14238/sp20.1.2018.50-7>.
- Chen, X. *et al.* (2024) "Immunological platelet transfusion refractoriness: current insights from mechanisms to therapeutics," *Platelets*, 35(1). Available at: <https://doi.org/10.1080/09537104.2024.2306983>.
- Cohn, C.S. (2020) "Platelet transfusion refractoriness: How do I diagnose and manage?," *Hematology (United States)*, 20(1), pp. 527–532. Available at: <https://doi.org/10.1182/HEMATOLOGY.2020000137>.
- Coleman, J.R. *et al.* (2020) "Female Platelets Have Distinct Functional Activity Compared to Male Platelets: Implications in Transfusion Practice and Treatment of Trauma-Induced Coagulopathy," *J Trauma Acute Care Surg.*, 87(5), pp. 1052–1060. Available at: <https://doi.org/10.1097/TA.0000000000002398>.
- Dacie, S.J. V. and Lewis, S.M. (2017) *Dacie and Lewis Practical Haematology*. Twelfth Ed. Edited by B.J. Bain *et al.* Elsevier.
- Dutra, V. de F. *et al.* (2022) "Platelet antibodies identification: comparison between two laboratory tests," *Hematology, Transfusion and Cell Therapy*, 44(3), pp. 365–368. Available at: <https://doi.org/10.1016/j.htct.2020.12.008>.
- Fan, J.B. *et al.* (2025) "The 'cytokine storm' in infection and sepsis: win the battle but lose the war," *Military Medical Research*, 12(1), pp. 1–21. Available at: <https://doi.org/10.1186/s40779-025-00678-0>.
- Gauer, R.L. *et al.* (2022) "Thrombocytopenia: Evaluation and Management," *American Family Physician*, 106(3), pp. 288–298.
- Hagino, T. *et al.* (2021) "Incidence and management of non-immune platelet transfusion refractoriness: A narrative review," *Annals of Blood*, 6(May). Available at: <https://doi.org/10.21037/AOB-20-93>.
- Hermening, D. (2019) *Modern Blood Banking & Transfusion Practices*. Seventh Ed. Edited by C. Fratantoro. Chocago, USA: Philadelphia : F.A. Davis Company.
- John, H. and Michael, H. (2021) "Guyton and Hall Textbook of Medical Physiology, 14th Edition."
- Kazemi, M.H. *et al.* (2020) "Human platelet antigen 1-6, 9 and 15 in the Iranian population: An anthropological genetic analysis," *Scientific Reports*, 10(1),

- pp. 1–10. Available at: <https://doi.org/10.1038/s41598-020-64469-4>.
- Kumawat, V. et al. (2015) "Prevalence of risk factors for platelet transfusion refractoriness in multitransfused hemato-oncological patients at tertiary care center in North India," *Asian Journal of Transfusion Science*, 9(1). Available at: <https://doi.org/10.4103/0973-6247.150953>.
- Kustilinarsih, Arsy, N. and Iskandar, M. (2024) "Gambaran Kejadian Penanganan Kasus Multitransfusi di UPD RSUP Fatmawati," *Jurnal Teknologi Bank Darah*, 3(2), pp. 54–57.
- Lubis, A.M. et al. (2017) "Hubungan Antibodi Anti Trombosit terhadap Respon Transfusi Trombosit pada Pasien Hemato- Onkologi yang Mendapatkan Multitransfusi Trombosit di RS Dr. Cipto Mangunkusumo," *Jurnal Penyakit Dalam Indonesia*, 2(4), p. 200. Available at: <https://doi.org/10.7454/jpdi.v2i4.86>.
- Lubis, A.M., Baskoro, M.O. and Yasmin, A. (2024) "Platelet Transfusion Refractoriness," *Plasmatology*, 18. Available at: <https://doi.org/10.1177/26348535241284460>.
- Maharani, E. and Noviar, G. (2018) *Imunohematologi dan Bank Darah*. Kementerian Kesehatan Republik Indonesia.
- Matsushashi, M. and Tsuno, N.H. (2018) "Laboratory testing for the diagnosis of immune-mediated thrombocytopenia," *Annals of Blood*, 3, pp. 41–41. Available at: <https://doi.org/10.21037/aob.2018.09.02>.
- Means, Robert T., Jr., et al. (2024) *Wintrobe's Clinical Hematology 15th edition 2024*. Edited by a W.K. business Lippincott Williams & Wilkins.
- Muhiddin, R. et al. (2019) "Analysis of human platelet antigen (HPA) in thrombocytopenia patients," *Indian Journal of Public Health Research and Development*, 10(10), pp. 1570–1575. Available at: <https://doi.org/10.5958/0976-5506.2019.03063.8>.
- Muhiddin, R. et al. (2020) *Analisis Perbedaan Frekuensi Genotipe Human Platelet Antigen (HPA), Konsentrasi Immunoglobulin-G Anti-HPA, Ekspresi mRNA IL-1 β pada Pasien Immune Thrombocytopenia Primer dan Sekunder, Fakultas Kedokteran Universitas Hasanuddin Makassar*. Hasanuddin University.
- MyBiosource (2024) *Human Anti Platelet Antibody (PAAb) ELISA kit (Competitive ELISA)*, MyBiosource. Available at: <https://doi.org/https://www.mybiosource.com/human-elisa-kits/anti-platelet-antibody-anti-pa-ab/7210707>.
- van Osch, T.L.J. et al. (2022) "Fc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on platelets," *Haematologica*, 107(10), pp. 2432–2444. Available at: <https://doi.org/10.3324/haematol.2021.280493>.
- Patel, P. et al. (2021) "Platelet Fc γ RIIA in immunity and thrombosis: Adaptive immunothrombosis," *Journal of Thrombosis and Haemostasis*, 19(5), pp. 1149–1160. Available at: <https://doi.org/10.1111/jth.15265>.
- Ren, J. et al. (2021) "Research progress on the immunological platelet transfusion refractoriness in patients with acute leukemia: A narrative review," *Annals of Blood*, 6(1), pp. 2–7. Available at: <https://doi.org/10.21037/AOB-20-63>.
- Sadaq, A., Arif, M. and Muhiddin, R. (2021) *Kadar Immunoglobulin-G (IgG) Anti-HPA dengan Metode Enzym Linked Immunosorbant Assay (ELISA) pada Pasien Immune Thrombocytopenia di Rumah Sakit Wahidin Sudirohusodo Makassar*. Hasanuddin University. Available at: <http://repository.unhas.ac.id:443/id/eprint/13909%0A>.

- Sarah K. Al-Ouda; Abdulmajeed A. Al-Banyan (2015) "Antibodies against human platelet alloantigens and human leucocyte antigen class 1 in Saudi Arabian multiparous women and multi-transfused patients," *Saudi Med J* 2015; Vol. 36 (6), 36(6), pp. 665–670. Available at: <https://doi.org/10.15537/smj.2015.6.11153>.
- Schmidt, A.E., Refaai, M.A. and Coppage, M. (2019) "HLA-Mediated Platelet Refractoriness An ACLPS Critical Review," *American Society for Clinical Pathology*, pp. 353–363. Available at: <https://doi.org/10.1093/AJCP/AQY121>.
- Solves, P. (2020) "Platelet transfusion in the real life," *Annals of Blood*, 5(June), pp. 2–5. Available at: <https://doi.org/10.21037/aob-20-30>.
- Song, T. et al. (2021) "Transfusion-induced platelet antibodies and regulatory T cells in multiply transfused patients," *Journal of Clinical Laboratory Analysis*, 35(7), pp. 1–8. Available at: <https://doi.org/10.1002/jcla.23864>.
- Twomey, L. et al. (2019) "Platelets: From Formation to Function," *Homeostasis - An Integrated Vision* [Preprint], (January 2019). Available at: <https://doi.org/10.5772/intechopen.80924>.
- Ukonu, U.C. and Ifeanyi, E. (2023) "Evaluation of Alloantibodies to human platelet antigen and Leucocyte antigen class 1 in Multitransfused patients in Owerri, Imo state," *International Journal of Current Research in Medical Sciences*, 9, pp. 38–44.
- Xiaoye Sun, Yifeng Cai, Hui Ni, H.C. (2023) "Therapeutic Efficacy of Platelet Transfusion and Analysis of Influencing Factors in 364 patients," *Acta Haematol* 1 June 2023; 146 (3), pp. 214–219. Available at: <https://doi.org/10.1159/000529542>.
- Youk, H.J. et al. (2022) "Evaluation and management of platelet transfusion refractoriness," *Blood Research*, 57(S1), pp. 6–10. Available at: <https://doi.org/10.5045/br.2022.2021229>.
- Yusuf, K. (2024) "Efek Sitokin Proinflamasi TnF - Alpha pada Penyakit Diabetes Melitus Tipe 2: Tinjauan Literatur Proinflammatory Cytokine TNF Alpha Effects in Type 2 Diabetes Mellitus Disease: a Literature Review," *Jurnal Integrasi Kesehatan dan Sains*, 6(1), pp. 22–26. Available at: <https://doi.org/10.29313/jiks.v6i1.12780>.
- Zhang, B. et al. (2025) "Distribution for platelet antibody in patients with immune-mediated platelet transfusion refractoriness," *Hematology (United Kingdom)*, 30(1). Available at: <https://doi.org/10.1080/16078454.2025.2549969>.
- Zhang, J. et al. (2026) "Association between platelet transfusion units and platelet transfusion refractoriness in patients with hematological disease: A cohort study in China," *Transfusion and Apheresis Science*, 65(1), p. 104368. Available at: <https://doi.org/10.1016/j.transci.2025.104368>.
- Zhang, J.C. et al. (2023) "Related donor platelet transfusion improves platelet transfusion refractoriness in hematological patients," *Frontiers in Medicine*, 10(March), pp. 1–7. Available at: <https://doi.org/10.3389/fmed.2023.983644>.
- Zou, Y. et al. (2025) "Analysis of influencing factors and predictive model construction for platelet transfusion efficacy in hematological patients," *Frontiers in Medicine*, 12(August), pp. 1–10. Available at: <https://doi.org/10.3389/fmed.2025.1632042>.